USA to LATAM expansion: manufacturing, compliance, and distribution.
Expanding a US brand into Latin America usually stalls on the same thing: the product was formulated, labeled, and registered for one market only. PMG is a US contract manufacturer that builds LATAM requirements into the specification from the start, so the second market does not require starting over.
A regulatory overview by market.
Each Latin American market runs its own registration pathway, in its own language, on its own timeline. Planning around them at formulation is far cheaper than reformulating after a US launch.
- ·Mexico — COFEPRIS (Federal Commission for the Protection against Sanitary Risk – Mexico) pathway; the largest first step for most US brands
- ·Brazil — ANVISA (National Health Surveillance Agency – Brazil) pathway; Portuguese-language submissions; the region's largest market by GDP
- ·Colombia — INVIMA (National Institute of Food and Drug Surveillance – Colombia) pathway; gateway to the Andean cluster
- ·Chile, Peru, Argentina — ISP, DIGEMID, and ANMAT pathways
- ·Caribbean — Puerto Rico falls under US regulation; shorter pathways elsewhere in the region
Manufacture in the USA, distribute through Miami.
Production runs in FDA (Food and Drug Administration)-registered, cGMP (Current Good Manufacturing Practice)-compliant facilities across our five-state US network, and export moves through the Miami gateway — the densest concentration of Latin American trade infrastructure in North America and the closest major US metro to both Mexico and South America.
Keeping manufacturing in the United States preserves one quality system, one set of batch records, and the "Made in USA" positioning that carries real weight with LATAM consumers in the beauty, supplement, and wellness categories — without the reformulation a separate regional manufacturer would require.
Bilingual project management, built in.
Regulatory submissions in Mexico and Brazil happen in the local language, and so do most distributor conversations. Our project management runs in English and Spanish as a baseline, with working Portuguese for Brazilian engagements, and our lead intake form is available in Spanish.
In practice the sequence looks like this: ingredient screening against COFEPRIS, ANVISA, and INVIMA restricted lists during formulation; label and claim review in the destination language; registration filings opened while US production is still running; then introductions to distributors in the target market.
Plan your LATAM expansion before you plan your reformulation.
Tell us which markets you are targeting and where your product stands today. A consultant will map the regulatory and distribution path with you.